HemoBioTech to Present "Need for Blood Substitute to Prevent HIV Transmission" at 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention

DALLAS, TX--(Marketwire - June 2, 2009) - Representatives from HemoBioTech, Inc. (OTCBB: HMBT) will present "Developing blood substitutes for the prevention of HIV transmission," at the 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. The conference, attended by over 5,000 of the world's leading scientists, physicians, community leaders and public health officials, takes place in Capetown, South Africa, from July 19 to 22nd, 2009.

An estimated 10 percent of HIV infections worldwide are attributed to contaminated blood used during blood transfusions. Other diseases such as Hepatitis B and Hepatitis C, which can greatly increase the risk of liver cancer as well as malaria, are also spread through this modality.

"A desperate need exists for a safe blood substitute, especially in developing countries, which would substantially reduce the number of new HIV infections occurring from unsafe blood transfusions," according to Dr. Roscoe M. Moore, Jr. former U.S. Assistant Surgeon General and Scientific Advisory Board member of HemoBioTech. "HemoTech would provide a safer alternative solution to this avoidable tragedy."

HemoTech™, developed by HemoBioTech, is a blood substitute that could replace blood in the body lost during trauma or from anemia. It also stimulates the body to produce new red blood cells. HemoTech could prevent transmission of HIV and other infectious agents from contaminated human blood. Based on human and animal studies, HemoTech does not show toxicity. Researchers believe that it is compatible with all blood types, can be available for administration within minutes and has a shelf life of over six months compared to the normal blood shelf life of 42 days.

"Millions around the world are in immediate need of an effective, safe blood substitute, and researchers have been trying to find one for years," said Arthur Bollon, Ph.D., Chairman and CEO of HemoBioTech. "We're pleased to have the opportunity to present the properties and potential benefits of HemoTech at IAS 09 in Capetown."

About HemoBioTech, Inc.

HemoBioTech is engaged in the commercial development of HemoTech, a novel human blood substitute technology developed by Texas Tech University Health Sciences Center scientists, Drs. Mario Feola and Jan Simoni, HemoTech is exclusively licensed by HemoBioTech from Texas Tech University System. HemoTech is composed of bovine hemoglobin that is chemically modified with ATP, Adenosine and GSH.

Researchers believe that HemoTech carries oxygen in the blood, and induces erythropoiesis (red blood cell production). The Company believes that HemoTech, due to its novel chemical structure, may possess properties that diminish the intrinsic toxicities that have plagued other attempts at developing blood substitutes, based upon pre-clinical and initial human clinical trials undertaken outside the U.S.

HemoTech is being subjected to further studies and testing to confirm and possibly expand on these initial results. HemoTech is being developed to help reduce or eliminate the danger resulting from acute blood loss in trauma, anemia, as well as for other conditions. HemoTech is an investigational biological drug that has not been approved by the U.S. Food and Drug Administration and cannot currently be marketed. Corporate headquarters are located at 5001 Spring Valley Road, Suite 1040-West, Dallas, Texas 75244.

Safe Harbor Statement

Except for historical information, the matters discussed in this news release may be considered "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of HemoBioTech and its management and are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a difference include,among others the successful pre-clinical development, the successful completion of clinical trials, the FDA review process and other governmental regulation, pharmaceutical collaborator interest and ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third party reimbursement, and other factors which are included in HemoBioTech's Annual Report on Form 10-K for the year ending December 31, 2007, as amended, and HemoBioTech's other reports filed with the Securities and Exchange Commission.

Contact Information: Contact: HemoBioTech, Inc. Arthur P. Bollon, PhD 972-455-8955 Chairman & CEO David Sheon WHITECOAT Strategies 202 547-2880